CD274 and neoplasm: The CMGCL can achieve great tumor targeting efficacy and upregulate programmed death ligand‐1 (PD‐L1) expression on LLC cells by simultaneously inducing glucose starvation and cuproptosis, thus effectively sensitizing αPD‐L1 therapy against subcutaneous or lung metastatic LLC tumors.